L
Linda Rogers-Freezer
Researcher at National Institutes of Health
Publications - 12
Citations - 8294
Linda Rogers-Freezer is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Antigen & Immunotherapy. The author has an hindex of 10, co-authored 12 publications receiving 7840 citations.
Papers
More filters
Journal ArticleDOI
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley,John R. Wunderlich,Paul F. Robbins,James Chih-Hsin Yang,Patrick Hwu,Douglas J. Schwartzentruber,Suzanne L. Topalian,Richard M. Sherry,Nicholas P. Restifo,Amy M. Hubicki,Michael R. Robinson,Mark Raffeld,Paul H. Duray,Claudia A. Seipp,Linda Rogers-Freezer,Kathleen E. Morton,Sharon Mavroukakis,Donald E. White,Steven A. Rosenberg +18 more
TL;DR: The adoptive transfer of highly selected tumor-reactive T cells directed against overexpressed self-derived differentiation antigens after a nonmyeloablative conditioning regimen resulted in the persistent clonal repopulation of T cells in cancer patients, leading to regression of the patients' metastatic melanoma as well as to the onset of autoimmune melanocyte destruction.
Journal ArticleDOI
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan,Mark E. Dudley,John R. Wunderlich,Michael S. Hughes,James Chih-Hsin Yang,Richard M. Sherry,Richard E. Royal,Suzanne L. Topalian,Udai S. Kammula,Nicholas P. Restifo,Zhili Zheng,Azam V. Nahvi,Christiaan R. de Vries,Linda Rogers-Freezer,Sharon Mavroukakis,Steven A. Rosenberg +15 more
TL;DR: The ability to specifically confer tumor recognition by autologous lymphocytes from peripheral blood by using a retrovirus that encodes a T cell receptor is reported.
Journal ArticleDOI
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw,Michael H. Kershaw,Michael H. Kershaw,Jennifer A. Westwood,Jennifer A. Westwood,Linda L. Parker,Gang Wang,Gang Wang,Zelig Eshhar,Sharon Mavroukakis,Donald E. White,John R. Wunderlich,Silvana Canevari,Linda Rogers-Freezer,Clara C. Chen,James Chih-Hsin Yang,Steven A. Rosenberg,Patrick Hwu +17 more
TL;DR: Large numbers of gene-modified tumor-reactive T cells can be safely given to patients, but these cells do not persist in large numbers long term, and future studies need to employ strategies to extend T cell persistence.
Journal ArticleDOI
Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
James Chih-Hsin Yang,Richard M. Sherry,Seth M. Steinberg,Suzanne L. Topalian,Douglas J. Schwartzentruber,Patrick Hwu,Claudia A. Seipp,Linda Rogers-Freezer,Kathleen E. Morton,Donald E. White,David J. Liewehr,Maria J. Merino,Steven A. Rosenberg +12 more
TL;DR: In this paper, a three-arm randomized study compared response rates and overall survival of patients with metastatic renal cell cancer (RCC) receiving high-dose or one of two low-dose interleukin-2 (IL-2) regimens.
Journal ArticleDOI
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.
Mark E. Dudley,John R. Wunderlich,James Chih-Hsin Yang,Patrick Hwu,Douglas J. Schwartzentruber,Suzanne L. Topalian,Richard M. Sherry,Francesco M. Marincola,Susan F. Leitman,Claudia A. Seipp,Linda Rogers-Freezer,Kathleen E. Morton,Azam V. Nahvi,Sharon Mavroukakis,Donald E. White,Steven A. Rosenberg +15 more
TL;DR: A nonmyeloablative-conditioning regimen that could be safely administered in conjunction with adoptive T-cell transfer and IL-2 in patients with metastatic melanoma is established.